Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer

[1]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[2]  J. Benítez,et al.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas , 2006, Journal of Clinical Pathology.

[3]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[4]  D. Birnbaum,et al.  BMC Cancer , 2003 .

[5]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[6]  Carsten Peterson,et al.  Transcriptional Dynamics of the Embryonic Stem Cell Switch , 2006, PLoS Comput. Biol..

[7]  François Vaillant,et al.  Steroid hormone receptor status of mouse mammary stem cells. , 2006, Journal of the National Cancer Institute.

[8]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[9]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[10]  Kazuhiro Yoshida,et al.  Expression of gastric mucin MUC5AC and gastric transcription factor SOX2 in ampulla of vater adenocarcinoma: comparison between expression patterns and histologic subtypes. , 2006, Oncology reports.

[11]  Daniel Birnbaum,et al.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. , 2006, Cancer research.

[12]  A. Ashworth,et al.  Basal-like breast carcinomas: clinical outcome and response to chemotherapy , 2006, Journal of Clinical Pathology.

[13]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[14]  Y. Tsutani,et al.  Histopathologic Evaluation of Stepwise Progression of Pancreatic Carcinoma with Immunohistochemical Analysis of Gastric Epithelial Transcription Factor SOX2: Comparison of Expression Patterns between Invasive Components and Cancerous or Nonneoplastic Intraductal Components , 2006, Pancreas.

[15]  C. Fletcher,et al.  Spindle Cell (Sarcomatoid) Carcinoma of the Breast: A Clinicopathologic and Immunohistochemical Analysis of 29 Cases , 2006, The American journal of surgical pathology.

[16]  J. Robertson,et al.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.

[17]  J. Benítez,et al.  Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.

[18]  M. Weiss,et al.  Reproductive Biology and Endocrinology Expression of Early Transcription Factors Oct-4, Sox-2 and Nanog by Porcine Umbilical Cord (puc) Matrix Cells , 2022 .

[19]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[20]  A. Olshen,et al.  Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. , 2006, Cancer research.

[21]  H. Kondoh,et al.  Convergence of Wnt and FGF signals in the genesis of posterior neural plate through activation of the Sox2 enhancer N-1 , 2005, Development.

[22]  T. Tsukamoto,et al.  Gastric-and-intestinal mixed-type intestinal metaplasia: aberrant expression of transcription factors and stem cell intestinalization , 2006, Gastric Cancer.

[23]  D. Birnbaum,et al.  Typical medullary breast carcinomas have a basal/myoepithelial phenotype , 2005, The Journal of pathology.

[24]  J. Reis-Filho.  Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005; 206: 451–457 , 2005, The Journal of pathology.

[25]  H. Schöler,et al.  Developmental cell biology: Regulatory networks in embryo-derived pluripotent stem cells , 2005, Nature Reviews Molecular Cell Biology.

[26]  Å. Borg,et al.  Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.

[27]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[28]  M. Katoh,et al.  Comparative genomics on SOX2 orthologs. , 2005, Oncology reports.

[29]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[30]  P. V. van Diest,et al.  The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.

[31]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[32]  Xi Chen,et al.  Reciprocal Transcriptional Regulation of Pou5f1 and Sox2 via the Oct4/Sox2 Complex in Embryonic Stem Cells , 2005, Molecular and Cellular Biology.

[33]  T. Tsukamoto,et al.  Sox2 expression in human stomach adenocarcinomas with gastric and gastric‐and‐intestinal‐mixed phenotypes , 2005, Histopathology.

[34]  L. Bégin,et al.  Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer , 2005, Clinical Cancer Research.

[35]  D. Ross,et al.  Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer , 2005, Breast Cancer Research.

[36]  W. Harris,et al.  Frizzled 5 Signaling Governs the Neural Potential of Progenitors in the Developing Xenopus Retina , 2005, Neuron.

[37]  D. Ambrosetti,et al.  Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation , 2005, The Journal of cell biology.

[38]  M. Tada,et al.  Octamer and Sox Elements Are Required for Transcriptional cis Regulation of Nanog Gene Expression , 2005, Molecular and Cellular Biology.

[39]  H. Denk,et al.  Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation?: Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers , 2005, The American journal of surgical pathology.

[40]  Michael Goggins,et al.  Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. , 2005, Cancer research.

[41]  Peter Devilee,et al.  Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. , 2005, Cancer research.

[42]  I. Bedrosian.  The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer , 2005 .

[43]  J. Cigudosa,et al.  Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers , 2005, Breast Cancer Research and Treatment.

[44]  M. Rao.  Conserved and divergent paths that regulate self-renewal in mouse and human embryonic stem cells. , 2004, Developmental biology.

[45]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[46]  Jorge S. Reis-Filho,et al.  Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.

[47]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[48]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[49]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[50]  S. Lakhani,et al.  Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue , 2004, The Journal of pathology.

[51]  L. Bégin,et al.  The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.

[52]  Y. Eishi,et al.  Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. , 2004, International journal of oncology.

[53]  J. Benítez,et al.  Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[54]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[55]  P. V. van Diest,et al.  In lymph node‐negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor , 2003, The Journal of pathology.

[56]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[58]  F. Gage,et al.  Genetic and functional differences between multipotent neural and pluripotent embryonic stem cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Cigudosa,et al.  Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  L. Pevny,et al.  SOX2 Functions to Maintain Neural Progenitor Identity , 2003, Neuron.

[61]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Reis-Filho,et al.  Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[64]  T. Tsukamoto,et al.  Stem cells and gastric cancer: Role of gastric and intestinal mixed intestinal metaplasia , 2003, Cancer science.

[65]  Marcel J T Reinders,et al.  Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. , 2002, Cancer research.

[66]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[67]  P. Chappuis,et al.  A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer , 2002, Journal of medical genetics.

[68]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Lakhani,et al.  CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation , 2001, British Journal of Cancer.

[71]  G. Moreno-Bueno,et al.  The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma , 2001, Modern Pathology.

[72]  B. Wullich,et al.  Novel amplification unit at chromosome 3q25–q27 in human prostate cancer , 2000, The Prostate.

[73]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[74]  S. Hirohashi,et al.  Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. , 2000, The American journal of surgical pathology.

[75]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[76]  J. Espada,et al.  Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. , 1995, The American journal of pathology.

[77]  P. Monaghan,et al.  Epidermal growth factor receptor expression on human breast luminal and basal cells in vitro. , 1995, Epithelial cell biology.

[78]  J. Foekens,et al.  Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. , 1994, The American journal of pathology.